BÜHLMANN IBDoc® Assay Citations Archives | Buhlmann Diagnostics Corp

Category: BÜHLMANN IBDoc® Assay Citations

US: BÜHLMANN IBDoc® is Not Available for Sale.
Canada: Health Canada Licence: 98903, Device class: 3
Canadian customers: A number of the publications in the citation list describe applications that are outside of product claims (Intended Use: IBDoc® is intended as an aid to the determination of the inflammatory status of the patient’s intestinal mucosa for inflammatory bowel disease (e.g. Crohn’s Disease and Ulcerative Colitis) monitoring.) thus they should be used for information only.

ECCO 2020 Poster – IBDoc Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)

IBDoc® Citation: Avery, P. et. al. N05: IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH).  ECCO 2020, Feb 12-15. Highlights from this Publication “ …This data also helps separate well from unwell patients, offering further opportunities to promote supported self-management in people with IBD and prioritisation of clinic appointments....” Read Citation Health
Continue Reading

ECCO 2020 Poster: IBD Home at GHP Stockholm Gastro Center in Sweden

IBDoc® Citation: S. Jäghult et. al.  N08: IBD Home at GHP Stockholm Gastro Center in Sweden. ECCO 2020, Feb 12-15. Highlights from this Publication “ …The majority (n = 24) stated that it was easy to install IBD Home. A total of nine patients noted that their participation in their own health care had increased...” “
Continue Reading

ECCO 2020 Poster – An evaluation of the impact of IBDoc

BÜHLMANN IBDoc®: Sugrue, K. et al.  N12: An evaluation of the impact of IBDoc in clinical practice 5 years after introduction.  ECCO 2020, Feb 12 – 15, 2020. Vienna, Austria. Highlights from this Publication “This study shows the benefits of using IBDoc® in clinical practice. It is central to facilitating a fast track system for patients
Continue Reading

IBDoc Key Literature List

IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters. Find valuable highlights from each publication and see the long list of studies that have utilized our assay!   View Citations Health Canada License: 98903 US: Not available for Sale in the US.
Continue Reading

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is Not Available for Sale in the US.
Continue Reading

Usability of IBDoc- Novel Fecal Calprotectin Home-Based Rapid Test

IBDoc® Citation: Røer MJ., 2019, Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice, Point of Care: September 2019 - Volume 18 - Issue 3 - p 85–91. doi: 10.1097/POC.0000000000000192 Highlights from this Publication “Clearly, the majority of the IBD patients found the home-based test valuable...” Read Citation Health Canada License: 98903
Continue Reading

Head-to-head comparison of three stool calprotectin tests for home use

IBDoc® Citation: Haisma et al. Head-to-head comparison of three stool calprotectin tests for home use.  Plos ONE. https://doi.org/10.1371/journal.pone.0214751  April 18, 2019 Highlights from this Publication “ …We observed that 119 of 125 IBDoc readings ≥ 500 μg/g were concordant with fCAL results (95%), compared to 35% and 49% for the QuantOnCal—IDK-Calprotectin and CalproSmart—Calprotectin-ALP pairs.…” “The CalproSmart
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh,  A,  Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625   DOI: doi.org/10.1093/ecco-jcc/jjy184  Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of
Continue Reading